Have a feature idea you'd love to see implemented?
Let us know!
LUNG Pulmonx Corp
Price (delayed)
$6.79
Market cap
$268.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.47
Enterprise value
$260.36M
Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment
Highlights
Pulmonx's gross profit has increased by 24% YoY and by 3.5% from the previous quarter
The revenue has grown by 22% YoY and by 3.6% from the previous quarter
The quick ratio is down by 15% since the previous quarter but it is up by 6% year-on-year
Pulmonx's debt has increased by 32% YoY
The company's equity fell by 25% YoY and by 7% QoQ
Key stats
What are the main financial stats of LUNG
Market
Valuations
Earnings
Shares outstanding
39.49M
Market cap
$268.12M
Enterprise value
$260.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.83
Price to sales (P/S)
3.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.28
Revenue
$79.3M
EBIT
-$52.83M
EBITDA
-$49.14M
Free cash flow
-$34.79M
Per share
Balance sheet
Liquidity
EPS
-$1.47
Free cash flow per share
-$0.89
Book value per share
$2.4
Revenue per share
$2.02
TBVPS
$4.2
Total assets
$167.4M
Total liabilities
$73.48M
Debt
$55.81M
Equity
$93.93M
Working capital
$122.63M
Debt to equity
0.59
Current ratio
7.7
Quick ratio
6.54
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
-62%
Gross margin
74.2%
Net margin
-72%
Operating margin
-73.4%
Return on assets
-33.5%
Return on equity
-53.9%
Return on invested capital
-41.7%
Return on capital employed
-35.4%
Return on sales
-66.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LUNG stock price
How has the Pulmonx stock price performed over time
Intraday
5.76%
1 week
7.1%
1 month
10.77%
1 year
-35.94%
YTD
-46.75%
QTD
-18.09%
Financial performance
How have Pulmonx's revenue and profit performed over time
Revenue
$79.3M
Gross profit
$58.81M
Operating income
-$58.21M
Net income
-$57.11M
Gross margin
74.2%
Net margin
-72%
Pulmonx's operating margin has increased by 24% YoY and by 5% from the previous quarter
Pulmonx's net margin has increased by 24% YoY and by 4.8% QoQ
Pulmonx's gross profit has increased by 24% YoY and by 3.5% from the previous quarter
The revenue has grown by 22% YoY and by 3.6% from the previous quarter
Growth
What is Pulmonx's growth rate over time
Valuation
What is Pulmonx stock price valuation
P/E
N/A
P/B
2.83
P/S
3.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.28
Pulmonx's EPS has increased by 9% YoY and by 2% from the previous quarter
The P/B is 40% lower than the 5-year quarterly average of 4.7 and 14% lower than the last 4 quarters average of 3.3
The company's equity fell by 25% YoY and by 7% QoQ
The price to sales (P/S) is 78% less than the 5-year quarterly average of 15.5 and 30% less than the last 4 quarters average of 4.8
The revenue has grown by 22% YoY and by 3.6% from the previous quarter
Efficiency
How efficient is Pulmonx business performance
Pulmonx's ROS has increased by 26% YoY and by 5% from the previous quarter
The company's return on equity fell by 23% YoY and by 6% QoQ
LUNG's return on invested capital is up by 22% year-on-year and by 8% since the previous quarter
The ROA fell by 6% YoY
Dividends
What is LUNG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LUNG.
Financial health
How did Pulmonx financials performed over time
Pulmonx's total assets is 128% more than its total liabilities
Pulmonx's total liabilities has increased by 24% YoY and by 2.8% from the previous quarter
The quick ratio is down by 15% since the previous quarter but it is up by 6% year-on-year
Pulmonx's debt is 41% lower than its equity
The debt to equity has surged by 74% year-on-year and by 5% since the previous quarter
Pulmonx's debt has increased by 32% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.